Search results for "C25"

showing 10 items of 566 documents

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phas…

2018

IF 5.503 (2017); International audience; In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU plus bevacizumab and anakinra (an IL-1β and α inhibitor) in patients with metastatic colorectal (mCRC) refractory to chemotherapy and anti-angiogenic therapy. Eligible patients had unresectable mCRC; were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumors with wild-type KRAS). Patients were treated with a simplified acid folinic plus 5-FU regimen and bevacizumab (5 mg/kg) both administered by intravenous infusion for 30 min…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyBevacizumabImmunologyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerNeutropeniaGastroenterologyclicial trial optimizationlcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicinetherapeutic trialsImmunology and Allergyil1colorectalnew targetsAnakinrabusiness.industryclinical trialmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOxaliplatinIrinotecanRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesischemoimmunotherapymdscbusinesslcsh:RC581-607medicine.drugOncoimmunology
researchProduct

Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19

2020

Since December 2019, a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly engulfed the world. Cancer patients infected with COVID-19 are considered to carry higher severity of the disease and higher mortality rate than common COVID-19 patients in previous studies. However, due to the poor clinical information on COVID-19 patients with cancer, the evidences that supported this conclusion are insufficient. At present, rather limited reports have analyzed the clinical data of breast cancer patients infected with COVID-19. Therefore, in this retrospective study, we described the clinical characteristics and the outcomes of 35 …

0301 basic medicinemedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)Diseasemedicine.disease_causelcsh:RC254-282Asymptomatic03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineclinical characteristicsCoronavirusOriginal Researchnon-cancerbusiness.industrySARS-CoV-2Mortality rateCancerRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisprognosismedicine.symptombusinessFrontiers in Oncology
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Postoperative intestinal fistula in primary advanced ovarian cancer surgery

2021

Antoni Llueca,1– 3 Anna Serra,1– 3 Maria Teresa Climent,1,2 Karina Maiocchi,2,4 Alvaro Villarin,2,4 Katty Delgado,2,5 Josep Mari-Alexandre,6 Juan Gilabert-Estelles,6,7 Paula Carrasco,3 Blanca Segarra,8 Luis Gomez,2,4 Juan Jose Hidalgo,3 Javier Escrig,3 Manuel Laguna2,4 On behalf of the MUAPOS working group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery1Department of Gynecology and Obstetrics, University General Hospital of Castellon, Castellón, Spain; 2Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Castellón, Spain; 3Department of Medicine, University Jaume I (UJI), Caste…

0301 basic medicinemedicine.medical_specialtyMultivariate analysiscomplicationsFistulalcsh:RC254-28203 medical and health sciences0302 clinical medicineintestinal fistulaMedicineIn patientintestinal leakageOriginal ResearchAdvanced ovarian canceradvanced ovarian cancer surgerybusiness.industrymedicine.diseaseDebulkinglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSurgeryBowel obstruction030104 developmental biologyOncologyCancer Management and Research030220 oncology & carcinogenesisConventional PCIPeritoneal Cancer Indexbusiness
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice

2020

Antigen-encoding, lipoplex-formulated RNA (RNA-LPX) enables systemic delivery to lymphoid compartments and selective expression in resident antigen-presenting cells. We report here that the rejection of CT26 tumors, mediated by local radiotherapy (LRT), is further augmented in a CD8+ T cell-dependent manner by an RNA-LPX vaccine that encodes CD4+ T cell-recognized neoantigens (CD4 neoantigen vaccine). Whereas CD8+ T cells induced by LRT alone were primarily directed against the immunodominant gp70 antigen, mice treated with LRT plus the CD4 neoantigen vaccine rejected gp70-negative tumors and were protected from rechallenge with these tumors, indicating a potent poly-antigenic CD8+ T cell r…

0301 basic medicinemedicine.medical_treatmentT cellImmunology03 medical and health sciences0302 clinical medicineAntigenmedicineImmunology and Allergyrna-lpxcd4+ t cellsradiotherapyRC254-282Antitumor activityLiposomeintegumentary systembusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRNARC581-607Radiation therapy030104 developmental biologymedicine.anatomical_structureOncologyLocal radiotherapy030220 oncology & carcinogenesisCancer researchImmunologic diseases. Allergybusinesscancer vaccinesneoantigensCD8OncoImmunology
researchProduct

The Role of p53 Signaling in Colorectal Cancer.

2021

Simple Summary The transcription factor p53 is a crucial tumor suppressor that regulates diverse cellular responses to protect against cancer development. Deactivating p53 signaling either by altering p53 regulators or by p53 mutations occurs frequently in human colorectal carcinoma (CRC). Forty-three percent of CRCs harbor p53 mutations that reduce wild-type p53 tumor suppressor activity and often provide neo-morphic functions, which contribute to tumorigenesis. In this review, we summarize wild-type p53 signaling, how it can be deregulated in CRC, and the functional and phenotypical effects of p53 mutations. We also discuss current therapeutic strategies of targeting p53. Abstract The tra…

0301 basic medicinewild type p53Cancer ResearchDNA repairCellular differentiationcolorectal cancerReview03 medical and health sciences0302 clinical medicinemedicineTranscription factorRC254-282gain-of-functionbiologyCell growthmutant p53CancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseUbiquitin ligasep53 signaling030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellbiology.proteinCancer researchMdm2cancer therapyp53 pathwayCancers
researchProduct

Cognitively-Based Compassion Training (CBCT (R)) in Breast Cancer Survivors: A Randomized Clinical Trial Study

2018

Breast cancer (BC) requires a significant psychological adaptation once treatment is finished. There is growing evidence of how compassion training enhances psychological and physical well-being, however, there are very few studies analyzing the efficacy of compassion-based Interventions on BC survivors. Objective. To study the efficacy of the CognitivelyBased Compassion Training (CBCT) protocol in a BC survivor sample on quality of life, psychological well-being, fear of cancer recurrence, self-compassion, and compassion domains and mindfulness facets. Furthermore, enrollment, adherence, and satisfaction with the intervention were also analyzed. Methods. A randomized clinical trial was des…

050103 clinical psychologyanimal structuresmedia_common.quotation_subjectfear of cancer recurrenceContext (language use)Compassionlaw.invention03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerRandomized controlled triallawwell-beingSurvivorship curvePsychological adaptationmedicine0501 psychology and cognitive sciencescontemplative trainingRC254-282media_commonbusiness.industry05 social sciencescompassion trainingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseself-compassionComplementary and alternative medicineOncology030220 oncology & carcinogenesisWell-beingbusinesssurvivorshipSelf-compassionClinical psychology
researchProduct

Isometric embeddings of snowflakes into finite-dimensional Banach spaces

2016

We consider a general notion of snowflake of a metric space by composing the distance by a nontrivial concave function. We prove that a snowflake of a metric space $X$ isometrically embeds into some finite-dimensional normed space if and only if $X$ is finite. In the case of power functions we give a uniform bound on the cardinality of $X$ depending only on the power exponent and the dimension of the vector space.

30L05 46B85 54C25 54E40 28A80Pure mathematicsmetric spacesGeneral MathematicsMathematicsofComputing_GENERALBanach space01 natural sciencesfunctional analysisCardinalityMathematics - Metric GeometryDimension (vector space)0103 physical sciencesFOS: MathematicsMathematics (all)Mathematics::Metric Geometry0101 mathematicsSnowflakeNormed vector spaceMathematicsConcave functionApplied Mathematicsta111010102 general mathematicsnormiavaruudetMetric Geometry (math.MG)normed spacesmetriset avaruudetMetric spacefractalsfraktaalit010307 mathematical physicsfunktionaalianalyysiMathematics (all); Applied MathematicsVector spaceProceedings of the American Mathematical Society
researchProduct

Use of a Perioperative Web-Based Exercise Program for a Patient with Barrett’s Carcinoma Scheduled for Esophagectomy

2019

A poor preoperative functional capacity increases the perioperative risk. Therefore, a web-based exercise approach has been initiated for a careful supervision and individual support of patients during their perioperative cancer therapy. Here, we present the data of a 57-year-old patient, scheduled for esophagectomy. Beside a five-week neoadjuvant chemoradiotherapy (CRT), the patient performed 10 weeks of a web-based prehabilitation exercise training (preconditioning) and continued the exercise program for 14 weeks after surgery. The patient performed 42 of 44 recommended training sessions in the preconditioning period in his home environment. This corresponds to a mean of 131 (±38) min of …

796 Sportexerciseperioperative carebarrett’s carcinomapreconditioningweb-basedCase ReportBarrett's carcinomaesophageal cancerprehabilitationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282796 Athletic and outdoor sports and gamesCase Reports in Oncology
researchProduct